SCHEMBL23948162

SCHEMBL23948162

C=CC(=O)N1CCN(c2nc(-c3ccccc3)nc3sc4c(c23)CCCC4)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 13/20 0.58
ALDH1A1 P00352 3/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
RECQL P46063 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
PRKCZ Q05513 5/20 0.57
CNR1 P21554 1/20 0.54
GPR55 Q9Y2T6 1/20 0.54
LMNA P02545 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
GAA P10253 1/20 0.53
HTT P42858 1/20 0.53
KDM4E B2RXH2 1/20 0.53
NPC1 O15118 1/20 0.53
HPGD P15428 1/20 0.53
NFKB1 P19838 1/20 0.53
CASP3 P42574 1/20 0.53
RAB9A P51151 1/20 0.53
NFKB2 Q00653 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29763654 1.00 PRKCI (0.58) PRKCIALDH1A1MEN1KMT2ARECQL
SCHEMBL23948165 0.85 ALDH1A1 (0.65) PRKCIALDH1A1MEN1KMT2ARECQL
SCHEMBL29763669 0.85 ALDH1A1 (0.65) PRKCIALDH1A1MEN1KMT2ARECQL
SCHEMBL29763678 0.84 ALDH1A1 (0.63) PRKCIALDH1A1MEN1KMT2ARECQL
SCHEMBL23948164 0.84 ALDH1A1 (0.63) PRKCIALDH1A1MEN1KMT2ARECQL
SCHEMBL23948163 0.82 GPR55 (0.63) PRKCIALDH1A1MEN1KMT2ARECQL
SCHEMBL29763653 0.82 GPR55 (0.63) PRKCIALDH1A1MEN1KMT2ARECQL
SCHEMBL24419929 0.81 ALDH1A1 (0.57) PRKCIALDH1A1MEN1KMT2ARECQL
SCHEMBL29763660 0.81 ALDH1A1 (0.57) PRKCIALDH1A1MEN1KMT2ARECQL
SCHEMBL24419568 0.78 ALDH1A1 (0.56) ALDH1A1MEN1KMT2ARECQLNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230047626-A1 SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS THE TRUSTEES OF INDIANA UNIVERSITY 2023-02-16 US disclosed
US-20220142973-A1 SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS THE TRUSTEES OF INDIANA UNIVERSITY 2022-05-12 US disclosed
WO-2021212010-A2 SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS THE TRUSTEES OF INDIANA UNIVERSITY (US) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047626-A1 SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS TP53, EIF2AK2, POLI PRKCI 448/4885ALDH1A1 2759/4885MEN1 3618/4885
US-20220142973-A1 SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS TP53, EIF2AK2, POLI PRKCI 448/4885ALDH1A1 2759/4885MEN1 3618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.